In summary, the present study suggests that the low dose of SMSP (50 mg/kg) effectively reduced the hepatic steatosis through the activation of SIRT1/AMPK-mediated signaling cascades in ethanol-treated rats. The gene discussed is SIRT1; the disease is fatty liver disease.